Phthalic Acid

Phthalic Acid

SCHEMBL9065494

CCCCCCCCc1ccc(C(=O)O)c(C(=O)O)c1CCCCCCCC.O=C(O)c1ccccc1C(=O)O

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 4/20 0.52
BID P55957 3/20 0.52
MCL1 Q07820 3/20 0.52
KAT8 Q9H7Z6 3/20 0.52
BCL2L1 Q07817 2/20 0.52
BAK1 Q16611 2/20 0.52
PPARG P37231 2/20 0.52
SAE1 Q9UBE0 2/20 0.52
EP300 Q09472 2/20 0.52
KAT5 Q92993 2/20 0.52
KAT2A Q92830 1/20 0.52
KAT2B Q92831 1/20 0.52
PLK1 P53350 4/20 0.46
F7 P08709 3/20 0.46
F3 P13726 3/20 0.46
MMP2 P08253 2/20 0.46
KDM4E B2RXH2 1/20 0.46
MAPT P10636 1/20 0.46
ALOX15 P16050 1/20 0.46
ECE1 P42892 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phthalic Acid SCHEMBL7126032 1.00 PPARA (0.52) PPARABIDMCL1KAT8BCL2L1
Phthalic Acid SCHEMBL27562902 1.00 PPARA (0.52) PPARABIDMCL1KAT8BCL2L1
Phthalic Acid SCHEMBL30774355 0.99 PPARA (0.51) PPARABIDMCL1KAT8BCL2L1
SCHEMBL10831711 0.94 PPARA (0.54) PPARABIDMCL1KAT8BCL2L1
SCHEMBL10831730 0.94 PPARA (0.54) PPARABIDMCL1KAT8BCL2L1
SCHEMBL826803 0.94 PPARA (0.54) PPARABIDMCL1KAT8BCL2L1
SCHEMBL8733022 0.94 PPARA (0.54) PPARABIDMCL1KAT8BCL2L1
SCHEMBL183977 0.94 PPARA (0.54) PPARABIDMCL1KAT8BCL2L1
SCHEMBL10833218 0.94 PPARA (0.54) PPARABIDMCL1KAT8BCL2L1
SCHEMBL724309 0.94 PPARA (0.54) PPARABIDMCL1KAT8BCL2L1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12569403-B2 Capsule with reduced powder leakage CAPSUGEL BELGIUM NV (BE) 2026-03-10 US disclosed
EP-4251126-B1 DOUBLE LAYERED DELAYED-RELEASE HARD CAPSULES CAPSUGEL BELGIUM NV (BE) 2026-02-18 EP disclosed
EP-4674411-A2 DOUBLE LAYERED DELAYED-RELEASE HARD CAPSULES Capsugel Belgium NV (BE) 2026-01-07 EP disclosed
CN-119907688-A Shading hard capsule containing magnesium oxide 比利时胶囊公司 2025-04-29 CN disclosed
EP-4069178-B1 CAPSULE WITH REDUCED POWDER LEAKAGE CAPSUGEL BELGIUM NV (BE) 2025-03-12 EP disclosed
EP-4467132-A2 DOUBLE LAYERED DELAYED-RELEASE HARD CAPSULES Capsugel Belgium NV (BE) 2024-11-27 EP disclosed
EP-4464313-A2 DOUBLE LAYERED DELAYED-RELEASE HARD CAPSULES Capsugel Belgium NV (BE) 2024-11-20 EP disclosed
US-20240317645-A1 Binder Composition and Method Thereof DESAI BINISH (US) 2024-09-26 US disclosed
CN-117306064-B Preparation process of disposable underpants with high elasticity and product thereof 广东启悦未来科技股份有限公司 2024-05-10 CN disclosed
CN-117306064-A Preparation process of disposable underpants with high elasticity and product thereof 广东启悦未来科技股份有限公司 2023-12-29 CN disclosed
US-20230017517-A1 CAPSULE WITH REDUCED POWDER LEAKAGE CAPSUGEL BELGIUM NV (BE) 2023-01-19 US disclosed
EP-3983477-B1 FILM, CAPSULE AND FILM-FORMING COMPOSITION COMPRISING WATER-SOLUBLE SALT AS OPACIFYING AGENT CAPSUGEL BELGIUM NV (BE) 2022-11-02 EP disclosed
EP-4069178-A1 CAPSULE WITH REDUCED POWDER LEAKAGE Capsugel Belgium NV (BE) 2022-10-12 EP disclosed
US-20220218619-A1 FILM, CAPSULE AND FILM-FORMING COMPOSITION COMPRISING WATER-SOLUBLE SALT AS OPACIFYING AGENT CAPSUGEL BELGIUM NV (BE) 2022-07-14 US disclosed
WO-2022112422-A1 DOUBLE LAYERED DELAYED-RELEASE HARD CAPSULES Capsugel France SAS (FR) 2022-06-02 WO disclosed
EP-3983477-A1 FILM, CAPSULE AND FILM-FORMING COMPOSITION COMPRISING WATER-SOLUBLE SALT AS OPACIFYING AGENT Capsugel Belgium NV (BE) 2022-04-20 EP disclosed
CN-101274997-B Biocidal compositions TROY CORP 2013-05-08 CN disclosed
CN-101274997-A Biocidal compositions TROY TECHNOLOGY CORP INC (US) 2008-10-01 CN disclosed
EP-0735005-A2 Process for treating recalcitrant compounds ZENON ENVIRONMENTAL INC. (CA) 1996-10-02 EP disclosed
US-5558774-A BIOOXIDATION, THERMOPHILIC MICROORGANISMS, WASTES FROM FOOD PROCESSING, METAL WORKING, PLASTICIZERS ZENON ENVIRONMENTAL INC. (CA) 1996-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12569403-B2 Capsule with reduced powder leakage EXOSC4, EXOSC10, CAP1 PPARA 3663/4885BID 4473/4885MCL1 4228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.